The FDA issued warning letters to 30 telehealth companies on March 3, 2026 for false or misleading claims about compounded GLP-1 products sold through their websites, per the FDA, 2026. It was the second batch of such letters since the agency's September 2025 crackdown on misleading direct-to-consumer pharmaceutical advertising.
This site publishes information, not medical advice. A warning letter is an enforcement demand, not a court ruling; the companies named can correct the cited practices. If you take or are considering a compounded GLP-1, bring questions to your clinician.
What claims did the FDA object to?
Two patterns dominated, per the FDA, 2026. Some sites suggested their compounded drugs were identical to FDA-approved products, which the agency rejects outright — compounded drugs are not FDA-reviewed for safety, effectiveness, or quality. Others branded the compounded products with the telehealth firm's own name or trademark, obscuring the pharmacy actually making them.
The scale of the campaign is notable: over roughly six months, the FDA sent thousands of warning letters — more than in the entire preceding decade, per the FDA, 2026. Commissioner Marty Makary emphasized that compounding should not be used to bypass the FDA approval process.
Related stories: FDA Moves to Restrict Compounded GLP-1 Copycats · Hims & Hers Posts $2.35B Year as GLP-1 Scrutiny Grows.
Why does enforcement matter if I already know compounded drugs differ?
Because most people meet these products through ads, not FDA labels. The letters show the agency treating telehealth marketing itself as the risk point: when a website wraps a pharmacy-made copy in a familiar brand name, a buyer can reasonably assume they are getting the same reviewed medicine as an approved drug, per the FDA, 2026. The volume of letters also signals that first-batch enforcement in fall 2025 did not clear the market.
What this changes for readers
If a telehealth site advertises a GLP-1, look past the branding to the dispensing pharmacy and the drug's approval status. An FDA-approved product carries an approved name like semaglutide under a brand the agency has reviewed; a compounded version does not, per the FDA, 2026. Check the FDA's warning-letter list before ordering, and ask your prescriber whether an approved option fits you.
The bottom line
On March 3, 2026, the FDA warned 30 telehealth companies over misleading compounded GLP-1 marketing, its second sweep since September 2025, and said thousands of letters have gone out in six months, per the FDA, 2026. The sensible next step for buyers is simple: verify approval status, not advertising, before you order.